Table 2.
Biomechanical Testing
| Parameter |
Experiment A
|
Experiment B
|
||||||||
| PO | PO | TD | TD | PO | TD | TD | TD | |||
| Dose (mg/kg/d) | 0 | 10 | 25 | 1 | 2.5 | 0 | 5 | 0.1 | 1 | 5 |
| N | 5 | 6 | 6 | 5 | 7 | 9 | 8 | 8 | 8 | 9 |
| 125.5 ± 8.2 | 135.0 ± 11 | 138.0 ± 1.1 | 178.1 ± 12* | 149 ± 7.6* | 135.4 ± 17.2 | 161.5 ± 13.7 | 192.6 ± 17* | 175 ± 15.8* | 154.2 ± 9.8 | |
| Maximum force (N) | ↑ 7.6% | ↑ 10% | ↑ 42% | ↑ 18.5% | ↑ 19% | ↑ 42% | ↑ 29% | ↑ 14% | ||
| 321 ± 20.2 | 559 ± 68.7* | 596.2 ± 102* | 566 ± 89* | 594 ± 26* | 252 ± 55 | 275.4 ± 38 | 477 ± 58* | 382 ± 49* | 419 ± 60* | |
| Stiffness (N/mm) | ↑ 74% | ↑ 85.7% | ↑ 76% | ↑ 85% | ↑ 9% | ↑ 90% | ↑ 52% | ↑ 67% | ||
| 35.4 ± 15 | 19.2 ± 1.6 | 26.6 ± 5.8 | 57.7 ± 5 | 27.1 ± 2.5 | 70.8 ± 16 | 62.6 ± 13.7 | 54 ± 8.9 | 54 ± 13.2 | 61 ± 8.7 | |
| Work to fracture (N-mm) | ↑ 63% | |||||||||
Biomechanical testing evaluated at 6 wk by three-point bending for experiments A and B in groups treated with PO and TD lovastatin. Number of femora tested for each treatment groups is indicated in the table. Results are expressed as mean ± SE. Numbers after arrows represent the percentage increase compared with vehicle-treated controls.
* p < 0.02, compared with vehicle control.